CYCLE GROUP HOLDINGS LIMITED
Get an alert when CYCLE GROUP HOLDINGS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-07-02 (in 2mo)
Last made up 2025-06-18
Watchouts
None on the register
Accounts
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Consolidated group
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Group is a profitable and cash generative pharmaceutical company, delivering revenue growth of 32% to $133,493k, Operating Profit of $41,049k and had net cash at 31 December 2024 of $58,544k. Management has prepared a cash flow forecast for a twelve-month period following the approval of the financial statements, showing continued growth of the business, which will enable the Group to continue as a going concern.”
Group structure
- CYCLE GROUP HOLDINGS LIMITED · parent
- Cycle Pharmaceuticals Ltd 100%
- Cycle Pharmaceuticals Incorporated 100%
- Varsity Pharmaceuticals Limited 100%
- Cycle Pharmaceuticals (Europe) Limited 100%
Significant events
- “On 10 January 2025, the Group purchased 100% of the shares of Banner Life Sciences LLC for upfront consideration of $51.6m, funded from cash on hand.”
- “On 18 March 2025, a new branded generic product VENXXIVA was launched in the US market.”
- “On 28 March 2025, the Group signed a Revolving Credit Facility, providing the Group with $100m of borrowing capacity.”
- “On 3 April 2025, the Group repaid all outstanding amounts due under the Deutsche Bank loan ($14.5m) and repurchased for cancellation all remaining warrants for $5m.”
- “On 18 April 2025, the Group signed a commercialisation agreement with Handa Pharma to commercialise PHYRAGO in the US, an approved treatment for rare forms of leukaemia.”
- “On 9 May 2025, the Group signed a commercialisation agreement with Lupin Inc to launch a branded generic form of glycerol phenylbutyrate.”
- “On 10 June 2025 the FDA approved HARLIKU (nitisinone) for the treatment of Alkaptonuria (AKU) a rare, inherited, metabolic disorder.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
7 active · 3 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| REINER, Andrea Curti | Secretary | 2025-11-13 | — | — |
| BUCKERIDGE, David James | Director | 2020-09-09 | Feb 1960 | British |
| CATES, Antony George | Director | 2021-09-24 | Mar 1966 | British |
| HARRISON, James Alexander | Director | 2020-06-30 | Feb 1974 | British |
| MOORE, Duncan Charles Mcnaught | Director | 2020-07-07 | Jan 1959 | British |
| REASON, Ross George | Director | 2025-08-01 | May 1961 | British |
| ROBINSON, William John | Director | 2020-07-07 | Feb 1948 | British |
Show 3 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| GOWING, Sarah Jean | Secretary | 2021-08-01 | 2025-11-13 |
| BRUNA, Alejandra, Dr | Director | 2021-04-01 | 2024-04-01 |
| REASON, Ross George | Director | 2020-07-07 | 2024-09-01 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Mr James Alexander Harrison | Individual | Shares 50–75%, Voting 50–75%, Appoints directors | 2020-06-30 | Active |
Filing timeline
Last 20 of 80 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-22 | SH03 | capital | Capital return purchase own shares | |
| 2026-04-02 | SH06 | capital | Capital cancellation shares | |
| 2026-03-18 | SH01 | capital | Capital allotment shares | |
| 2026-02-19 | SH01 | capital | Capital allotment shares | |
| 2025-12-09 | SH01 | capital | Capital allotment shares | |
| 2025-12-08 | SH03 | capital | Capital return purchase own shares | |
| 2025-11-14 | SH06 | capital | Capital cancellation shares | |
| 2025-11-13 | AP03 | officers | Appoint person secretary company with name date | |
| 2025-11-13 | TM02 | officers | Termination secretary company with name termination date | |
| 2025-11-12 | SH01 | capital | Capital allotment shares | |
| 2025-10-21 | SH01 | capital | Capital allotment shares | |
| 2025-08-13 | AA | accounts | Accounts with accounts type group | |
| 2025-08-01 | AD01 | address | Change registered office address company with date old address new address | |
| 2025-08-01 | AP01 | officers | Appoint person director company with name date | |
| 2025-07-07 | SH03 | capital | Capital return purchase own shares | |
| 2025-07-01 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-06-21 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2025-06-16 | SH06 | capital | Capital cancellation shares | |
| 2025-06-05 | SH01 | capital | Capital allotment shares | |
| 2025-04-08 | MR04 | mortgage | Mortgage satisfy charge full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 19
- Capital events
- 12
- Officers appointed
- 2
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
Latest filed period vs the prior one